Co-Authors
This is a "connection" page, showing publications co-authored by Guiqiang Wang and Hong Zhao.
Connection Strength
1.599
-
The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive. Infect Dis Poverty. 2021 Mar 31; 10(1):45.
Score: 0.937
-
Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 08; 21(1):495.
Score: 0.222
-
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 05; 21(1):488.
Score: 0.221
-
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020 May; 55(5):105954.
Score: 0.219